Trial record 17 of 35 for:
Open Studies | "Peritonitis"
Procalcitonin as a Marker for the Length of Antibiotic Treatment in Peritonitis and Intra-abdominal Infections
The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2012 by University of Lausanne Hospitals.
Recruitment status was Recruiting
Information provided by (Responsible Party):
Nicolas DEMARTINES, University of Lausanne Hospitals
First received: July 23, 2009
Last updated: April 21, 2012
Last verified: April 2012
Procalcitonin level used for determining length of antibiotic treatment in peritonitis and intra-abdominal infections. Hypothesis is that length of antibiotic use can be shortened by this method.
Secondary or Tertiary Peritonitis
||Observational Model: Cohort
Time Perspective: Prospective
||Etude Prospective Sur l'Impact de l'Utilisation de la Procalcitonine Dans l'évaluation de la Poursuite ou de l'arrêt du Traitement Antibiotique Empirique Lors de péritonites et d'Infections Intra-abdominales
Primary Outcome Measures:
- antibiotic treatment length, hospitalisation length without antibiotic, infection recurrence, antibiotic cost [ Time Frame: at one month and during hospital stay ] [ Designated as safety issue: Yes ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
control group: antibiotic use and length of treatment as defined by guidelines
Prospective randomized trial
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
hospitalized patients with SIRS due to peritonitis or intra-abdominal infections
- More than 18 yo
- Patient requiring surgery for peritonitis or intra-abdominal infection following: perforation, necrosis, previous operation...
- Mannheim Peritonitis score > 14
- SIRS present
- Probability of survival > 72h
- Informed consent by patient/relatives
- No SIRS
- Long date corticoid treatment
- Thyroid medullary carcinoma
- Anaphylactic shock
- Acute hepatic deficiency
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01155739
|University Hospital of Lausanne
|Lausanne, Switzerland, 1011 |
|Contact: Steve Aellen, MD email@example.com |
|Principal Investigator: Steve Aellen, MD |
University of Lausanne Hospitals
||Steve Aellen, MD
||Department of visceral surgery, university hospital
No publications provided
||Nicolas DEMARTINES, professor of surgery, University of Lausanne Hospitals
History of Changes
|Other Study ID Numbers:
|Study First Received:
||July 23, 2009
||April 21, 2012
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on November 27, 2014
Digestive System Diseases